RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Supercan, Plitican, Vergentan, Litican
Synonyms :
alizapride
Class :
Antiemetics/dopamine receptor modulators
Brand Name :
Supercan, Plitican, Vergentan, Litican
Synonyms :
alizapride
Class :
Antiemetics/dopamine receptor modulators
Dosage Forms & Strengths
Oral
75mg
Parenteral
2mg/kg
5mg/kg
Orally
once a day
75mg- 300mg orally once daily in divided doses
Refer to adult dosing
it increases the efficacy of CNS depressants
it increases the efficacy of CNS depressants
it increases the efficacy of CNS depressants
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of anti parkinsonism agents
it decreases the efficacy of anti parkinsonism agents
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
the efficacy of Dopamine agonists will be decreased when alizapride is used in combination
may increase the CNS depressant effect
may decrease the therapeutic effect of anti-Parkinson agents
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may enhance the serum concentration of CYP2D6 Inhibitors
alizapride: they may increase the antiplatelet effect of Agents with antiplatelet agent
alizapride: they may increase the antiplatelet effect of Agents with antiplatelet agent
alizapride: they may increase the antiplatelet effect of Agents with antiplatelet agent
alizapride: they may increase the antiplatelet effect of Agents with antiplatelet agent
alizapride: they may increase the antiplatelet effect of Agents with antiplatelet agent
the therapeutic effect of apomorphine may be reduced
the therapeutic effect of aripiprazole may be reduced
the risk of adverse effects may be increased
the therapeutic effect of brexipiprazole may be reduced
the therapeutic effects of bromocriptine may be reduced
the therapeutic effect of cabergoline may be reduced
the risk of adverse effects may be increased
the therapeutic effect of fenoldopam may be reduced
the therapeutic effect of metergoline may be reduced
the therapeutic effect of pramipexole may be reduced
the therapeutic effect of quinagolide may be reduced
the risk of adverse effects may be increased
it may increase the effect of CNS depressants
it may increase the effect of CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
hydrocodone/chlorpheniramine/pseudoephedrine
may increase the CNS depressant activity of CNS depressants
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect of CNS Depressants
Actions and spectrum:
Alizapride is an antagonist of dopamine. It blocks D2 receptors in the CTZ (chemoreceptor trigger zone), thereby prevents nausea and vomiting
Frequency not defined
Diarrhea
Dizziness
Drowsiness
Headache
Galactorrhoea
Amenorrhea
Extrapyramidal symptoms
Do not drive vehicles or operate machinery
Contraindication/Caution:
Contraindication:
Sub-occlusion
GI perforation
Pheochromocytoma
Pregnancy consideration:
USFDA pregnancy category: C
Lactation:
The data about the excretion of drugs into breast milk is not known
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Alizapride is an antiemetic drug structurally similar to metoclopramide
Pharmacodynamics:
It is an antagonist of dopamine
Pharmacokinetics:
Absorption
It is rapidly absorbed when administered orally
Distribution
Metabolism
Alizapride undergoes hepatic metabolism primarily through the cytochrome P450 enzyme system, with CYP3A4 playing a significant role in the process. The metabolites are excreted in the urine
Half-life:
3 hours
Administration:
Administer the drug as advised by the doctor
Patient information leaflet
Generic Name: alizapride
Why do we use alizapride?
Alizapride is an antiemetic drug used to treat nausea and vomiting that are primarily caused by chemotherapy, cancer, surgery, etc.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
